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BACKGROUND: The standard treatment for acute pancreatitis (AP) is still based on supportive care. The search for a new drug
that could change the natural history of the disease is a continuing challenge for many researchers. The aim of this study is to
evaluate the effect of a cyclooxygenase-2 (COX-2) inhibitor on experimental AP in rats.
METHODS: The animals were divided into 2 groups: Group 1 (n = 30)—animals with taurocholate-induced AP treated with
parecoxib (40 mg/kg). Group 2 (n = 30)—animals with taurocholate-induced AP that received saline. The COX-2 inhibitor
(parecoxib) was injected immediately after AP induction, through the penis dorsal vein. The parameters evaluated were histology,
serum levels of amylase, IL-6 and IL-10, and mortality rate. RESULTS: The serum levels of IL-6 and IL-10 in the parecoxib-
treated group were lower than the control group. The amylase serum levels and the mortality rate remained unchanged in the
treated animals. Histologic morphology also was unaltered, except for fat necrosis, which was higher in parecoxib-treated rats.
CONCLUSION: Inhibition of Cox-2 decreases the systemic release of inflammatory cytokines, but has a poor effect on the
direct pancreas injury caused by taurocholate.
KEYWORDS: Acute pancreatitis, COX-2 inhibition, Parecoxib, Interleukins
INTRODUCTION
Acute pancreatitis (AP) is an inflammatory condition
of the pancreas characterized by abdominal pain and el-
evated pancreatic enzymes in the blood.1 There are several
etiologies for this disturbance,2 but the exact pathophysi-
ological mechanism is still not completely understood.
The disease involves a complex cascade of events.2–5 It
starts with intracellular activation of enzymes and the sub-
sequent lesion of acinar cells, leading to a local and systemic
inflammatory response.2 Activation of complement and sec-
ondary release of C5a has a significant role in the recruit-
ment of inflammatory cells.3 Activation of these cells pro-
vokes the release of proinflammatory cytokines, metabolites
of arachidonic acids, and oxygen free radicals (OFRs), which
may eliminate the antioxidant defenses of the cells.5 These
substances interact with the microcirculation, increasing vas-
cular permeability and inducing thrombosis and hemorrhage,
ultimately leading to tissue necrosis.
The cyclooxygenase (COX) enzyme (also known as
PGH syntase or PG endoperoxydase) catalyzes the limit-
ing reaction of prostaglandin E
2
 production.6 There are at
least 2 isoforms of cyclooxygenases.7 The isoform known
as COX-1 is constitutive (present in several healthy tissues,
such as the kidneys and the gastrointestinal tract). It is be-
lieved that this isoform has a pivotal role in the protection
and maintenance of mucosal integrity.8 The isoform COX-
2 is inducible, and its detection in noninflamed tissues is
controversial. It also appears to play a role in the course
of inflammation .9 The expression of COX-2 is stimulated
by proinflammatory cytokines, such as TNF-alpha and IL-
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1; it is inhibited by anti-inflammatory mediators, such as
interleukin-10 (IL-10), IL-4, and by the transforming
growth factor-beta (TGF-beta).10,11
Zabel-Langhennig et al demonstrated that COX-2
mRNA as well as its serum level are elevated in the set-
ting of AP.12 This elevation is more pronounced in the early
stages of the inflammatory process, when the enzyme acts
as a proinflammatory agent. In the late stages of the disor-
der, COX-2 may have anti-inflammatory properties, al-
though this still is matter of debate.13
Other studies have shown the beneficial effect of pre-
vious inhibition of COX-2 or the knock-out of its gene in
experimental AP.14–17 Song et al,16 using a model of experi-
mental cerulein-induced AP, showed that pharmacological
inhibition of COX-2 before AP induction resulted in the
reduction of inflammatory mediators, in diminished neu-
trophil recruitment, and in improvement of pulmonary and
pancreatic histologic lesions. However, the efficacy of
COX-2 inhibition has not yet been evaluated in a clinical
setting; moreover, some reports have shown an association
of administration of COX-2 inhibitor and AP.18–21
Taking this controversy into account, the aim of this
study was to determine the effect of COX-2 inhibition on
experimental taurocholate-induced AP.
MATERIALS AND METHODS
Sixty male Wistar rats, provided by the Medical Inves-
tigation Laboratory #37 (LIM-37) and managed according
to Guide for Care and Use of Laboratory Animals (1996)
were used. The study protocol was approved by Institutional
Ethics Committee for animal use in research studies. The
animals were housed in a room with a temperature of 23
± 1ºC and a 12-hour light-dark cycle. The night before the
experiment, food and water was offered ad libitum.
Rats were divided into 2 groups: Group I (n = 30): rats
with taurocholate-induced AP that received a single dose
of parecoxib (40 mg/kg) iv through the penis dorsal vein
immediately after the induction of AP; Group II (n = 30):
rats with taurocholate-induced AP that received a saline in-
jection immediately after AP induction.
AP induction
We induced acute pancreatitis according to a previously
reported procedure22 (Figure 1).
Sacrifice
After a 2-hour period, 10 rats of each group were re-
anesthetized and underwent a new laparotomy in order to
obtain blood samples (by cardiac puncture) and pancreatic
tissue. The pancreata were removed and carefully dissected,
freed of all adjacent fat and lymph nodes. The animals were
sacrificed by exsanguination after this process.Histologic
alterations and serum levels of IL-6, IL-10, and amylase
were assessed.
The remaining 20 rats of each group were watched for
a 72-hour period to determine the mortality rate.
Amylase and Interleukin Serum Levels
Blood samples were immediately centrifuged at 3000
g for 10 minutes at 0ºC, and the supernatant stored at -20ºC.
In all rats, amylase serum levels were assessed by
Bernfeld’s method23 as modified by Jamieson et al.24
Serum IL-6 and IL-10 levels were determined by en-
zyme-linked immunoabsorbent assay (ELISA), using
BioSource International CytoscreenTM kits (BioSource In-
ternational, Camarillo, California, USA)
Histological Evaluation
Representative tissue samples collected from the duo-
denal (proximal) and splenic (distal) parts of the pancreas
were fixed in 10% formalin for 24 h and embedded in par-
affin. Five-micrometer-thick sections were stained with
hematoxylin and eosin, and the degree of tissue damage
was graded in a blinded fashion by a single pathologist,
using an established scoring system.25Statistical Analysis
Results are reported as mean + SE. Parametric data were
evaluated by the Student t test. Nonparametric data were
evaluated by the Mann-Whitney U test. To compare mor-
tality rates, the Kaplan-Meier log-rank test was employed.
Significant difference was declared when P < 0.05.
Figure 1- Injection of taurocholate into the main pancreatic duct (MPD)
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RESULTS
Serum levels of IL-6 and IL-10 were lower in rats that
received the COX-2 inhibitor, (Figures 2 and 3). In con-
trast, the ratio of IL-6 to IL-10 was unaltered.
Histologic evaluation of edema, hemorrhage, and aci-
nar necrosis did not show any difference between the two
groups, but fat necrosis was worse in the parecoxib-treated
rats (Table 1).
Serum levels of amylase and mortality rates remained
unaltered (Figure 4).
DISCUSSION
The standard treatment of AP is still based on support-
ive care 26. The search for new drugs that could alter the
natural history of the disease is a continuing challenge for
many researchers. Several substances have been tested in
some studies in an attempt to block the effects of inflam-
matory mediators that have an established role in the
pathogenesis of AP. The tested agents include antioxidants,
antiplatelet aggregating factor (anti-PAF), nonspecific
COX-inhibitors, H+K+ pump inhibitors, and somatostatine-
analogues.27-31 The drawback of these studies is that, in gen-
eral, the treatment was carried out before the induction of
AP, and although some of these substances may have
brought some benefits in experimental AP models, appli-
cation in the clinical setting is limited by the impossibil-
ity of predicting the occurrence of the disease. On the other
hand, in the present study, the aim was to determine
whether the activity of COX-2 is relevant to the progres-
sion of the disease. Therefore, the COX-2 inhibitor
parecoxib was administered immediately after the onset of
AP, which also does not directly relate to the real clinical
scenario. Nevertheless, this has allowed us to highlight im-
portant findings about the role of COX-2 in the pathophy-
siology of the disease.
COX-2 is considered a proinflammatory enzyme that
is expressed in the early phases of inflammation (neu-
trophil-dominated phase). Much is known about the
proinflammatory role of COX-2 in a variety of acute and
chronic inflammatory conditions, including arthritis, in-
flammatory bowel disease, and asthma, but very little is
known regarding its potential role in acute pancreatitis. In
Table 1. Effect of Cox-2 inhibition on fat necrosis, according
to Schmidt’s scale,30 showing higher fat necrosis in
parecoxib-treated rats (P = 0. 0.0289).








Figure 2- Effect of Cox-2 inhibition on serum levels of IL-6, evaluated by
an ELISA method, showing lower levels in parecoxib-treated rats (AP: Mean
± SEM = 135.6 ± 31.14, n = 7; and AP + Parecoxib: Mean ± SEM = 61.64 ±
14.19, n =14 (P = 0.0216).
Figure 3. Effect of Cox-2 inhibition on serum levels of IL-10, evaluated by
an ELISA method, showing lower level in parecoxib-treated rats ( AP - Mean
±SEM = 146.3 ± 23.48, n=8 and AP + Parecoxib - Mean ±SEM = 88.43 ±
12.93, n=14 with p = 0.0288).
Figure 4- Effect of Cox-2 inhibition on mortality rate, showing a better late
survival rate in parecoxib-treated rats, but with no significant difference
between the groups (Chi square = 0.1398; P = 0.7085; n = 20).
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a study using a cerulein model of severe AP, Song et al
found that mRNA levels of pancreatic COX-2 rose within
15 minutes of the start of cerulein administration and that
pancreatic COX-2 protein levels were increased within 4
h of cerulein administration.16 These observations suggest
that COX-2 might play an important role in regulating the
severity of cerulein-induced AP. However, the mechanisms
by which COX-2 might promote inflammation in taurocho-
late-induced AP are not immediately obvious. We consid-
ered the possibility that COX-2 might cause direct dam-
age to epithelial ductal cells and recruit inflammatory cells
to the local tissue, leading to edema and hemorrhage.
Cytokine production by these inflammatory cells probably
involves activation of nuclear factor – κB (NF-κB).32 The
proinflammatory effects of COX-2 in experimental AP may
be multifactorial and involve, among other things, altera-
tions in heat-shock proteins (HSPs), inducible NO synthase
(iNOS) expression, and neutrophil function.
In the present study, we demonstrated that parecoxib,
a second generation COX-2 inhibitor, infused immediately
after AP induction, diminished serum levels of IL-6 and
IL-10; however, there was no decrease of serum levels of
amylase or any benefit regarding pancreatic histologic dam-
age, and the survival rate remained unaltered. Therefore,
we postulate that the pancreatic lesion established in the
taurocholate model of AP may be impossible to revert and,
perhaps, that treatment should be directed to the preven-
tion of the systemic damage. In an analogue study, Alhan
et al17 found that celecoxib (a first-generation COX-2 in-
hibitor), injected i.p. 6 hours after the induction of necro-
tizing AP, decreased myeloperoxidase (MPO) and
malondialdehyde (MDA) levels in the pancreatic tissue.
These authors concluded that celecoxib has an antioxidant
effect, because there is no evidence that prostaglandins con-
tribute to acinar cell injury. In addition, serum levels of IL-
6 were also found to be reduced, and no differences in
mortality rate were observed. In our study, the COX-2 in-
hibitor was injected intravenously immediately after AP
induction. The dosage we employed was 4-fold higher than
previously reported by other authors14,16 The option for such
a huge dosage was purely empiric, as an attempt to main-
tain very low levels of COX-2.
Considering the proinflammatory action of IL-6, the re-
duction of its blood levels after the onset of AP, could have,
in theory, beneficial effect in the evolution of the disease,
even hours after induction. However, this could not be dem-
onstrated by histologic evaluation in the present investiga-
tion. The role of IL-6 on AP is complex and controversial.33
Multiple studies have correlated the severity of the disease
with IL-6 blood levels. Some of these studies have sug-
gested that levels of IL-6 in patients with acute pancreati-
tis may be predictive of disease severity.34-36 It has also been
found that IL-6 is responsible for the synthesis of acute-
phase proteins.37
The cytokine IL-6, is thought to be induced, at least par-
tially, by NF-κB activation. Slogoff et al, using a cerulein
model of AP, showed that IL-6 levels were elevated in mice
treated with COX-2 inhibitors, despite attenuated pancre-
atic inflammation and a decrease in NF-κB activation.38
This finding suggests that the stimulus for IL-6 secretion
remained intact, despite a lower NF-κB activity; however,
it did not elucidate whether IL-6 is linked to the ameliora-
tion of AP in mice. In the present report, although serum
levels of IL-6 were diminished, this was not associated with
any benefit regarding the pancreatic histologic damage. On
the other hand, in the report by Alhan et al,17 the lower level
of IL-6 correlated with a lower level of MPO and MDA in
the pancreatic tissue. This discrepancy observed among the
3 studies may be due to the differences in the experimen-
tal models as well as in the study designs.
Previous studies demonstrated that the kinetics of NF-
κB activation after induction of cerulein-induced pancreati-
tis are biphasic; NF-κB is initially activated during the first
15 minutes after cerulein administration, peaks at 30 min-
utes, decreases during the next hour; a second peak occurs
between 3 and 6 hours.39 Considering these results, it is pos-
sible that the initial peak of NF-κB remains intact after COX-
2 inhibition in the cerulein model, thus resulting in IL-6 re-
lease. Nevertheless, the kinetics of NF-κB activation and IL-
6 release in taurocholate-induced AP is not clear.
Improved survival has been demonstrated in an experi-
mental model of taurocholate-induced AP in rats treated
with a NF-κB inhibitor, despite a lack of attenuation of his-
tologic severity.40 So, it is also possible that there is no cor-
relation between COX-2 and the NF-κB pathway in the
early events of this experimental model.
With IL-10 being an anti-inflammatory cytokine42 and
one of the major mediators of compensatory anti-inflam-
matory response syndrome,43 the decrease in its level after
parecoxib treatment was an unexpected finding in the
present study. This could explain the unchanged histologic
damage and survival rate. There are some possible expla-
nations for this result. As previously mentioned, anti-in-
flammatory cytokines, such as IL-10, decrease
cyclooxygenase-2 expression. Because COX-2 was already
inhibited by parecoxib, it is possible that its serum levels
were decreased since there was no stimulus for its increase.
Perhaps the main reason for a compensatory anti-inflam-
matory response by IL-10 is the COX-2 activity itself. An-
other possibility is that the increase of IL-10 is coupled with
an increase in IL-6 as a mechanism to keep the inflamma-
tory response under control. The finding that the ratio of
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IL-6 to IL-10 was also unchanged suggests that the two
cytokines decreased in a way directly proportional. Some
studies have shown that increases in IL-10 concentration
also follow a biphasic pattern (in the first days and about
10 days later).44 However, the significance of elevated se-
rum IL-10 levels in AP is unclear, as is its connection with
the COX-2 pathway.
In conclusion, the treatment with a COX-2 inhibitor
might lower serum levels of at least two cytokines, but there
was no amelioration of the survival rate or histologic pan-
creatic damage. The potential benefits of this effect are still
unclear; therefore, further investigation is needed to better
elucidate how COX-2 inhibition might change the natural
course of AP.
Note: the authors would like to express their gratitude
for Sandra Aparecida Nassa Sampietre and Nilza Aparecida
Trindade Molan. We are in debt with them.
RESUMO
de Almeida JLJ, Jukemura J , Coelho AMM, Patzina RA,
Machado MCC , Cunha JEM. Inibição da Ciclo-Oxigenase-
2 na Pancreatite Aguda Grave Experimental. Clinics.
2006;61(4):301-6.
INTRODUÇÃO: O tratamento padrão para a pancreatite
aguda permanece baseado em medidas de suporte. A busca
por uma droga que altere a história natural da doença ainda
é um desafio para muitos pesquisadores. O objetivo deste
estudo é avaliar o efeito de um inibidor da COX-2 na
pancreatite aguda grave experimental (PA) em ratos.
MÉTODO: Os animais foram divididos em dois Grupos:
Grupo 1 (n=30) - animais com PA induzida por taurocolato
e tratados com parecoxib (40mg/Kg). Grupo 2 (n=30) -
animais com PA induzida por taurocolato que receberam
solução salina. O inibidor de COX-2 (parecoxib) foi injetado
imediatamente após a indução, através da veia dorsal do
pênis. Os parâmetros avaliados foram histologia, níveis
séricos de amilase, IL-6 e IL-10 e taxa de mortalidade.
RESULTADOS: Os níveis séricos de IL-6 e IL-10 foram
menores do que no grupo controle. Os níveis séricos de
amilase e a taxa de mortalidade permaneceram inalteradas.
A análise histológica também não mostraram alterações,
exceto pela necrose gordurosa, que foi maior nos animais
controle.
CONCLUSÃO: A inibição da COX-2 pode reduzir a
liberação sistêmica de pelo menos duas citocinas, mas tem
pouco efeito na lesão pancreática direta causada pelo
taurocolato.
UNITERMOS: Pancreatite aguda, Inibição da COX-2,
Parecoxib, Interleucinas
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